Pyoderma
Drug research and approvals for pyoderma: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 18, 2026, 4 studies of pyoderma are recruiting on ClinicalTrials.gov, Health Canada has authorized 4 drug trials for it since 2013, and FDA has 0 approved and 3 open orphan designations naming it.
- Recruiting worldwide: 4
- Trials authorized in Canada: 4
- FDA orphan approvals: 0
- EU medicines: 0
Recruiting Now
Newest start dates first, of 4 recruiting on ClinicalTrials.gov ↗- Topical Ruxolitinib in the Treatment of Adults With Pyoderma GangrenosumNCT07783412 · Phase 2 · Oregon Health and Science University · starts Sep 1, 2026
- A Clinical Study Evaluating the Efficacy and Safety of SHR-1139 Injection in Adult Patients With Ulcerative Pyoderma…NCT07337564 · Phase 2 · Shandong First Medical University · starts Jan 29, 2026
- A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma GangrenosumNCT06624670 · Phase 3 · LEO Pharma · starts Feb 5, 2025
- A Real-World Registry of Chronic Wounds and UlcersNCT02280733 · Not reported · U.S. Wound Registry · starts Jan 1, 2005
Drug Pipeline
5 in phase 3, 6 in phase 2, 1 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition- Gevokizumab
- Phase 3 Interleukin-1 beta negative allosteric modulator
- Adalimumab
- Phase 3 TNF-alpha inhibitor
- Vilobelimab
- Phase 3 Complement C5 inhibitor
- Oxygen
- Phase 3 Essential for cellular homeostasis
- Dioxydine
- Phase 3
- Secukinumab
- Phase 2 Interleukin 17A inhibitor
- Canakinumab
- Phase 2 Interleukin-1 beta inhibitor
- Etrasimod
- Phase 2 Sphingosine 1-phosphate receptor Edg-1 agonist
- Bermekimab
- Phase 2 Interleukin-1 alpha inhibitor
- Ixekizumab
- Phase 2 Interleukin 17A inhibitor
- Spesolimab
- Phase 2 IL36 receptor antagonist
- Cravacitinib
- Early phase 1 Tyrosine-protein kinase TYK2 negative allosteric modulator
How Its Trials Ended
35 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 10 whose ending is known, 10% met their primary endpoint, 0% missed it and 90% stopped early.
- Completed, result not reported1234%
- Ongoing1029%
- Stopped: other or unclear720%
- Status unknown39%
- Met its primary endpoint13%
- Stopped: enrollment or feasibility13%
- Stopped: sponsor or business decision13%
Trials Authorized in Canada
Newest first; search them all in Canada trials| Aug 22, 2024 | A multi-centre, randomised, placebo-controlled, double blind, parallel-group trial to evaluate safety and efficacy of spesolimab (bi 655130) in adult patients…Spesolimab (bi 655130) | Boehringer Ingelheim (Canada) Ltd Ltee | Ongoing |
| Feb 12, 2019 | Open label exploratory phase IIa trial to investigate the safety and efficacy of ifx-1 in treating subjects with pyoderma gangrenosumIFX-1 (CACP29) | Inflarx GmbH | Closed |
| Jan 16, 2015 | A 2-year, open-label, safety extension study of gevokizumab in subjects with pyoderma gangrenosumGevokizumab | Xoma US LLC | Ongoing |
| Jan 16, 2015 | A randomized, double-blind, placebo-controlled study of the efficacy and safety of gevokizumab in treating active ulcers of pyoderma gangrenosumGevokizumab | Xoma US LLC | Ongoing |
FDA Orphan Designations
Approved first, then open designations, newest first| Nov 9, 2025 | InfliximabTreatment of pyoderma gangrenosum | Oddifact SAS | Designated |
| Apr 16, 2025 | Spesolimab-sbzoTreatment of pyoderma gangrenosum | LEO Pharma Inc. | Designated |
| Jun 27, 2022 | VilobelimabTreatment of pyoderma gangrenosum | InflaRx N.V. | Designated |
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA